A phase I study indicates that the combination of utomilumab, an investigational antibody that binds CD137, plus pembrolizumab is safe and well tolerated, yielding sustained responses in patients with various solid cancers.
from Cancer via ola Kala on Inoreader http://ift.tt/2aedINW
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου